Literature DB >> 28536496

Link between dysregulated hypoxia signaling and aberrant methylation in clear cell renal cell carcinoma?

Niraj Shenoy1.   

Abstract

Entities:  

Year:  2017        PMID: 28536496      PMCID: PMC5422419          DOI: 10.21147/j.issn.1000-9604.2017.02.10

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


× No keyword cloud information.
Dysregulated pseudo-hypoxia (through its effects on cell survival, angiogenesis, metabolism, invasion) and epigenetic dysregulation [through widespread suppression of tumor suppressor genes involved in cell cycle, apoptosis, adhesion, immune evasion, etc. (1)] are considered to be the two central driving pathogenic features in the progression of clear cell Renal Cell Carcinoma (ccRCC) (2,3). These two features also play a significant role in mediating the chemoresistance of radioresistance of ccRCC. The finding of increased DNA methyltransferase 1 (DNMT1) expression in ccRCC by Liet al. (4) provides one mechanistic reason for the previously reported genome wide aberrant methylation seen in ccRCC, leading to the suppression of various important tumor suppressor genes (3,5). Strikingly, this finding may also establish a link between the driver hypoxia inducible factor (HIF) pathway and aberrant methylation seen in von Hippel-Lindau (VHL) defective ccRCC. BiallelicVHL gene defects are seen in up to 75% of patients with sporadic ccRCC (6). pVHL, product of theVHL tumor suppressor gene, plays a key role in oxygen sensing by targeting HIF-α for ubiquitination and proteasomal degradation. In the absence ofVHL activity, HIF-α is stabilized, translocates to the nucleus, where it combines with the constitutionally expressed HIF-1β to form heterodimers that bind to hypoxia response elements (HREs) in a wide range of gene promoters, leading to a pseudo-hypoxic state (7,8). Interestingly, HIF-1α has been shown to enhance the expression of DNMT1 and DNMT3b in cardiac fibroblasts. The promoter region of DNMT1 and DNMT3a was seen to have well defined HREs (9). Therefore, it is possible that the finding of enhanced expression of DNMT1 in ccRCC is due to the enhanced HIF-α stabilization seen in ccRCC. This potential link between dysregulated hypoxia signaling and aberrant methylation in ccRCC needs to be further studied with correlative studies on HIF-1α/HIF-2α expression and DNMT1 expression in ccRCC and with HIF-α knockdown impact on DNMT1 expression and genome wide methylation in ccRCC. Establishing a link between the driver HIF pathway and the genome-wide aberrant methylation in ccRCC could have a significant translational impact, as we could then expect HIF modifying treatment strategies to also have a restorative effect on the aberrant epigenetics in ccRCC.
  8 in total

Review 1.  Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective.

Authors:  N Shenoy; L Pagliaro
Journal:  Ann Oncol       Date:  2016-06-20       Impact factor: 32.976

2.  Aberrant DNA methyltransferase 1 expression in clear cell renal cell carcinoma development and progression.

Authors:  Ming Li; Ying Wang; Yongsheng Song; Renge Bu; Bo Yin; Xiang Fei; Qizhen Guo; Bin Wu
Journal:  Chin J Cancer Res       Date:  2014-08       Impact factor: 5.087

3.  Kidney cancer is characterized by aberrant methylation of tissue-specific enhancers that are prognostic for overall survival.

Authors:  Caroline Y Hu; Davoud Mohtat; Yiting Yu; Yi-An Ko; Niraj Shenoy; Sanchari Bhattacharya; Maria C Izquierdo; Ae Seo Deok Park; Orsolya Giricz; Nishanth Vallumsetla; Krishna Gundabolu; Kristin Ware; Tushar D Bhagat; Masako Suzuki; James Pullman; X Shirley Liu; John M Greally; Katalin Susztak; Amit Verma
Journal:  Clin Cancer Res       Date:  2014-06-10       Impact factor: 12.531

4.  Hypoxia-induced epigenetic modifications are associated with cardiac tissue fibrosis and the development of a myofibroblast-like phenotype.

Authors:  Chris J Watson; Patrick Collier; Isaac Tea; Roisin Neary; Jenny A Watson; Claire Robinson; Dermot Phelan; Mark T Ledwidge; Kenneth M McDonald; Amanda McCann; Osama Sharaf; John A Baugh
Journal:  Hum Mol Genet       Date:  2013-12-02       Impact factor: 6.150

Review 5.  VHL, the story of a tumour suppressor gene.

Authors:  Lucy Gossage; Tim Eisen; Eamonn R Maher
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

6.  Comprehensive molecular characterization of clear cell renal cell carcinoma.

Authors: 
Journal:  Nature       Date:  2013-06-23       Impact factor: 49.962

7.  Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study.

Authors:  Kjeld P van Houwelingen; Boukje A C van Dijk; Christina A Hulsbergen-van de Kaa; Leo J Schouten; Hanneke J M Gorissen; Jack A Schalken; Piet A van den Brandt; Egbert Oosterwijk
Journal:  BMC Cancer       Date:  2005-06-02       Impact factor: 4.430

Review 8.  Role of DNA methylation in renal cell carcinoma.

Authors:  Niraj Shenoy; Nishanth Vallumsetla; Yiyu Zou; Jose Nahun Galeas; Makardhwaj Shrivastava; Caroline Hu; Katalin Susztak; Amit Verma
Journal:  J Hematol Oncol       Date:  2015-07-22       Impact factor: 17.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.